Advanced Pipeline
- CardiAMP – autologous minimally processed bone marrow cells (a patient’s own cells)
- NK1R+ MSC –allogenic culture expanded mesenchymal stem cells derived from bone marrow (donor-derived)
Both programs provide compelling and synergistic approaches to replicating the natural response of bone marrow cells to cardiac injury. CardiAMP harnesses the potential of autologous minimally processed bone marrow cells, using a pre-procedure screening test to identify patients most likely to benefit from the therapy. NK1R+ MSCs utilize younger, universal donor mesenchymal stem cells and may be appropriate for patients who are not optimal candidates for the CardiAMP therapy.
The NK1R+ MSC platform is also being advanced clinically for the pulmonary indication of acute respiratory distress.News
06 Dec
Fierce Biotech
BioCardia's off-the-shelf cell therapy for heart failure to enter first-in-human study
01 Dec
Empowered Patient Podcast
Optimizing Autologous Cell Therapy to Treat Cardiovascular Disease with Dr. Peter Altman
29 Oct
UW Health
UW Health Treats First Patient in U.S. with Investigational Cell Therapy for Heart Disease
29 Oct
Greenbay CBS
Neenah musician, educator pursues dream after being first in the world to undergo ‘Investigational Cell Therapy’
29 Oct
04 Mar
Henry Ford Health System
Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
press releases
16 Mar Have questions?
CALL US NOW
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
EMAIL US NOW
: info@biocardia.com
biocardia takes a new and comprehensive
approach to heart failure
By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.